Leerink Partners Reiterates Buy Rating on uniQure N.V.
Leerink Partners maintains its buy rating on uniQure N.V. with a $70 price target.
Key Points
- Leerink Partners reiterated its buy rating on uniQure N.V. with a price target of $70 as of June 18, 2026.
- uniQure N.V. shares are trading at $48.16, with a market cap of approximately $3.04 billion and a 52-week range of $8.73 to $71.5.
- Insider transactions at uniQure included sales and purchases by key personnel, with significant institutional activity among peers.
On June 18, 2026, Leerink Partners reiterated its buy rating on uniQure N.V. (NasdaqGS:QURE), setting a price target of $70. This comes as the company's stock trades at $48.16.
Analysts Set New Price Targets
On June 18, 2026, Leerink Partners maintained its buy rating on uniQure N.V., setting a price target of $70. RBC Capital also kept its buy rating with a $65 target on the same day. Earlier, HC Wainwright & Co. maintained a buy rating and set a target of $50 on May 6, 2026. However, Goldman Sachs maintained a hold rating with a much lower target of $10 on April 20, 2026.
Other Institutional Activity in uniQure N.V.
Among uniQure's institutional investors, Aberdeen Group PLC significantly increased its holdings by 1,627,746 shares, ending with 5,306,386 shares valued at about $86.8 million. Two Sigma Investments, LP also grew its stake by 1,224,587 shares, reaching a total of 2,675,871 shares worth approximately $43.8 million. On the other hand, AVOro Capital Advisors LLC trimmed its position by 190,405 shares, now holding 5,959,595 shares valued at $97.4 million.
uniQure N.V. Stock Snapshot
Shares of NasdaqGS:QURE traded near $48.16. uniQure N.V. has a market cap of roughly $3.04 billion. The stock has seen a 52-week low of $8.73 and a high of $71.5. It has a current ratio of 10.4 and a quick ratio of 10.0, with a debt-to-equity ratio of 365.4, reflecting its financial leverage.
Insider Buying and Selling at uniQure N.V.
Recent insider activity at uniQure included sales and purchases by key personnel. On June 15, 2026, Balachandran Madhavan executed both a planned sale of 10,000 shares at $27.85 and a purchase of 10,000 shares at $8.49. Chief Legal Officer Jeannette Potts sold 5,237 shares at an average price of $27.67 on the same day.
About uniQure N.V.
uniQure N.V., headquartered in Amsterdam, Netherlands, is a biotechnology company focused on developing treatments for rare diseases. It offers HEMGENIX for hemophilia B and is working on gene therapy candidates for Huntington's disease, epilepsy, ALS, and Fabry disease. Founded in 1998, the company is led by CEO Matthew Craig Kapusta and employs 221 people.
Bottom Line
Leerink Partners' reiteration of a buy rating and a $70 price target reflects confidence in uniQure N.V.'s prospects. With a strong pipeline in rare disease treatments, the company's stock performance is closely watched by investors. As always, it's important to remember that analyst ratings and institutional holdings are backward-looking and may not reflect the current market conditions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.